Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


28.06.2021

3 Am J Hematol
3 Ann Hematol
1 Biochem Pharmacol
2 Blood
1 BMC Cancer
10 Bone Marrow Transplant
7 Br J Haematol
2 Cancer
1 Cancer Chemother Pharmacol
1 Eur J Haematol
1 Exp Cell Res
2 Int J Hematol
2 J Clin Oncol
1 J Immunol
8 Leuk Lymphoma
6 Leuk Res
1 Leukemia
1 PLoS Comput Biol
3 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. JABBOUR E, Patel K, Jain N, Duose D, et al
    Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.
    Am J Hematol. 2021 Jun 23. doi: 10.1002/ajh.26281.
    PubMed         Abstract available

  2. LAZARIAN G, Munger M, Quinquenel A, Dilhuydy MS, et al
    Clinical and biological characteristics of leukemia cutis in Chronic Lymphocytic Leukemia: a study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2021 Jun 21. doi: 10.1002/ajh.26274.
    PubMed        

  3. HELBIG DR, Abu-Zeinah G, Bhavsar E, Christos PJ, et al
    Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
    Am J Hematol. 2021;96:E187-E189.
    PubMed        


    Ann Hematol

  4. VIRK H, Rana S, Sharma P, Bose PL, et al
    Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
    Ann Hematol. 2021 Jun 22. pii: 10.1007/s00277-021-04574.
    PubMed         Abstract available

  5. GREIL R, Tedeschi A, Moreno C, Anz B, et al
    Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Ann Hematol. 2021;100:1733-1742.
    PubMed         Abstract available

  6. GADGEEL M, AlQanber B, Buck S, Taub JW, et al
    Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.
    Ann Hematol. 2021;100:1695-1700.
    PubMed         Abstract available


    Biochem Pharmacol

  7. KIM JH, Lee SJ, Kang KW, Lee BH, et al
    CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
    Biochem Pharmacol. 2021;190:114658.
    PubMed         Abstract available


    Blood

  8. NG AP
    Unraveling a T-ALL Tapestri.
    Blood. 2021;137:726-727.
    PubMed        

  9. GILL S
    DARTs point the way forward in AML.
    Blood. 2021;137:720-721.
    PubMed        


    BMC Cancer

  10. FATIMA M, Kakar SJ, Adnan F, Khan K, et al
    AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia.
    BMC Cancer. 2021;21:713.
    PubMed         Abstract available


    Bone Marrow Transplant

  11. STYCZYNSKI J, Tridello G, Koster L, Iacobelli S, et al
    Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.
    Bone Marrow Transplant. 2019 Aug 27. pii: 10.1038/s41409-019-0624.
    PubMed         Abstract available

  12. AMBERGE S, Kramer M, Schrottner P, Heidrich K, et al
    Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome.
    Bone Marrow Transplant. 2019 Sep 18. pii: 10.1038/s41409-019-0678.
    PubMed         Abstract available

  13. WETHMAR K, Matern S, Esseling E, Angenendt L, et al
    Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.
    Bone Marrow Transplant. 2020 Jan 30. pii: 10.1038/s41409-020-0801.
    PubMed         Abstract available

  14. KANDA J, Umeda K, Kato K, Murata M, et al
    Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation.
    Bone Marrow Transplant. 2020 Mar 11. pii: 10.1038/s41409-020-0853.
    PubMed         Abstract available

  15. REES MJ, Spencer A, Browett P, Alvaro F, et al
    High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission.
    Bone Marrow Transplant. 2020 May 6. pii: 10.1038/s41409-020-0924.
    PubMed        

  16. MCCAUGHAN G, Ma D, Moore J
    Two cases of successful autologous stem cell transplantation in patients with multiple myeloma and concurrent chronic myeloid leukaemia.
    Bone Marrow Transplant. 2020 Aug 8. pii: 10.1038/s41409-020-01025.
    PubMed        

  17. DEYA-MARTINEZ A, Alonso-Saladrigues A, Garcia AP, Faura A, et al
    Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia.
    Bone Marrow Transplant. 2021;56:376-386.
    PubMed         Abstract available

  18. RAUTENBERG C, Bergmann A, Pechtel S, Fischermanns C, et al
    Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation.
    Bone Marrow Transplant. 2021;56:442-450.
    PubMed         Abstract available

  19. JIANG S, Fan Y, Fang Y, Hou C, et al
    The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2020 Sep 5. pii: 10.1038/s41409-020-01048.
    PubMed         Abstract available

  20. SHIMOMURA Y, Hara M, Hirabayashi S, Kondo T, et al
    Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
    Bone Marrow Transplant. 2021 Jun 21. pii: 10.1038/s41409-021-01380.
    PubMed        


    Br J Haematol

  21. DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
    Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Br J Haematol. 2021;192:577-588.
    PubMed         Abstract available

  22. MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
    Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2021;192:474-483.
    PubMed         Abstract available

  23. FLOETH M, Elges S, Gerss J, Schwoppe C, et al
    Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2021;192:494-503.
    PubMed         Abstract available

  24. BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
    Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
    Br J Haematol. 2021;192:484-493.
    PubMed         Abstract available

  25. ALI AM, Cooper J, Walker A, Jones D, et al
    Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
    Br J Haematol. 2021;192:665-667.
    PubMed        

  26. HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
    A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Br J Haematol. 2021;192:e77-e81.
    PubMed        

  27. EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
    Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
    Br J Haematol. 2021;192:e81-e84.
    PubMed        


    Cancer

  28. SASAKI K, Kantarjian HM, Morita K, Short NJ, et al
    Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Cancer. 2021 Jun 17. doi: 10.1002/cncr.33655.
    PubMed         Abstract available

  29. HOPPMANN AL, Chen Y, Landier W, Hageman L, et al
    Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33760.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  30. TOKSVANG LN, Andres-Jensen L, Rank CU, Niinimaki R, et al
    Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Cancer Chemother Pharmacol. 2021 Jun 18. pii: 10.1007/s00280-021-04316.
    PubMed         Abstract available


    Eur J Haematol

  31. PUNGOLINO E, D'adda M, De Canal G, Trojani A, et al
    Nilotinib induced Bone Marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: final report of the PhilosoPhi34 study.
    Eur J Haematol. 2021 Jun 17. doi: 10.1111/ejh.13680.
    PubMed         Abstract available


    Exp Cell Res

  32. LIU Z, Zheng W, Liu Y, Zhou B, et al
    Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells.
    Exp Cell Res. 2021 Jun 19:112708. doi: 10.1016/j.yexcr.2021.112708.
    PubMed         Abstract available


    Int J Hematol

  33. KOBAYASHI T, Ubukawa K, Fujishima M, Takahashi N, et al
    Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.
    Int J Hematol. 2021;113:600-605.
    PubMed         Abstract available

  34. ONO R, Ashiarai M, Hirabayashi S, Mizuki K, et al
    Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Int J Hematol. 2021;113:297-301.
    PubMed         Abstract available


    J Clin Oncol

  35. MYERS RM, Li Y, Barz Leahy A, Barrett DM, et al
    Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2003458. doi: 10.1200/JCO.20.03458.
    PubMed         Abstract available

  36. DESAI PM, Brown J, Gill S, Solh MM, et al
    Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2001739. doi: 10.1200/JCO.20.01739.
    PubMed         Abstract available


    J Immunol

  37. MONTRESOR A, Toffali L, Fumagalli L, Constantin G, et al
    Activation of Protein Tyrosine Phosphatase Receptor Type gamma Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
    J Immunol. 2021 Jun 23. pii: jimmunol.2001462. doi: 10.4049/jimmunol.2001462.
    PubMed         Abstract available


    Leuk Lymphoma

  38. QU S, Jia Y, Wang H, Ai X, et al
    STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms.
    Leuk Lymphoma. 2021;62:1506-1509.
    PubMed        

  39. SENAPATI J, Dhawan R, Aggarwal M, Kumar P, et al
    Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country.
    Leuk Lymphoma. 2021;62:1514-1517.
    PubMed        

  40. LADHA A, Hui G, Cheung E, Berube C, et al
    Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.
    Leuk Lymphoma. 2021;62:1510-1513.
    PubMed        

  41. RAMKISSOON LA, Buhlinger K, Nichols A, Coombs CC, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941928.
    PubMed        

  42. HADJIAGGELIDOU C, Douganiotis G, Tsirou K, Verrou E, et al
    A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941932.
    PubMed        

  43. SINGH J, Facey A, O'Malley F, Ryland GL, et al
    Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941935.
    PubMed        

  44. YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
    Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
    PubMed         Abstract available

  45. LEPRETRE S, Touboul C, Flinois A, Kutikova L, et al
    Quality of life in adults with acute lymphoblastic leukemia in France: results from a French cross-sectional study.
    Leuk Lymphoma. 2021 Jun 24:1-11. doi: 10.1080/10428194.2021.1941924.
    PubMed         Abstract available


    Leuk Res

  46. KIM YJ, Jung SH, Hur EH, Choi EJ, et al
    Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
    Leuk Res. 2021;103:106540.
    PubMed         Abstract available

  47. ISHDORJ G, Nugent Z, Squires M, Kost S, et al
    Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
    Leuk Res. 2021;109:106628.
    PubMed         Abstract available

  48. GENESCA E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, et al
    Adverse prognostic impact of complex karyotype (>/=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).
    Leuk Res. 2021;109:106612.
    PubMed         Abstract available

  49. HUNTER AM, Al Ali N, Mai A, Shah S, et al
    Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
    Leuk Res. 2021;109:106640.
    PubMed        

  50. GUPTA SK, Singh P, Chhabra R, Verma M, et al
    Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
    Leuk Res. 2021;109:106641.
    PubMed         Abstract available

  51. ZAMANI A, Fattahi Dolatabadi N, Houshmand M, Nabavizadeh N, et al
    miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia.
    Leuk Res. 2021;109:106643.
    PubMed         Abstract available


    Leukemia

  52. ABDALLAH MG, Niibori-Nambu A, Morii M, Yokomizo T, et al
    RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner.
    Leukemia. 2021 Jun 19. pii: 10.1038/s41375-021-01268.
    PubMed        


    PLoS Comput Biol

  53. SUSAK H, Serra-Saurina L, Demidov G, Rabionet R, et al
    Efficient and flexible Integration of variant characteristics in rare variant association studies using integrated nested Laplace approximation.
    PLoS Comput Biol. 2021;17:e1007784.
    PubMed         Abstract available


    PLoS One

  54. MOHSENI M, Kucharski C, K C RB, Nasrullah M, et al
    Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL).
    PLoS One. 2021;16:e0251719.
    PubMed         Abstract available

  55. KOVY P, Orfi Z, Bors A, Kozma A, et al
    Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
    PLoS One. 2021;16:e0253386.
    PubMed         Abstract available

  56. KIM SK, Goughnour PC, Lee EJ, Kim MH, et al
    Identification of drug combinations on the basis of machine learning to maximize anti-aging effects.
    PLoS One. 2021;16:e0246106.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  57. LEE YL, Ito K, Pi WC, Lin IH, et al
    Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: